

Treatment of Peritonitis: CAPD vs APD Patients

Peritonitis Management: Case-based Presentations
Monday, March 6, 2023

Vesh Srivatana MD
Assistant Professor of Clinical Medicine
Director of Peritoneal Dialysis



Member
 **NewYork-Presbyterian**
Regional Hospital Network

Disclosures

- None


Case 1

- 60 year old woman, 70kg
- ESRD secondary to IgA Nephropathy on PD for about 2 years.
- Presenting with cloudy fluid and abdominal pain
 - Current prescription CAPD
 - 2000cc Exchanges, 4x/day
 - No Residual Renal Function

Case 1 Treatment

- Empiric treatment: Intermittent dosing regimen
 - 1g Ceftazidime IP daily
 - 2g Vancomycin IP every 5 days
 - following levels of vancomycin to maintain a level > 15 mg/L
- Await culture/cell count data to determine final antibiotics choice and course duration

ISPD Guideline Based Treatment



Principles of Effective Treatment

- Adequate Coverage
 - Empiric Gram Positive and Gram Negative Coverage
- Adequate Dose
 - Adjust for residual renal function and dialysis clearance of medication
 - Intermittent vs Continuous dosing
- Adequate Delivery
 - Correct Administration
- Adequate Duration
 - Based on culture/sensitivities

Empiric Gram Positive Coverage

- First generation Cephalosporin or Vancomycin
- Most popular 1st gen cephalosporin would be cefazolin

Table 5. IP antibiotic dosing recommendations for treatment of peritonitis.

Antibiotic	Intermittent (1 exchange daily for at least 6 h)	Continuous (all exchanges)
Aminoglycosides		
Amikacin	2 mg/kg daily ¹⁷³	Not advised
Gentamicin	0.6 mg/kg daily ^{174,175}	Not advised
Netilmicin	0.6 mg/kg daily ¹⁶⁵	Not advised
Tobramycin	0.6 mg/kg daily	Not advised
Cephalosporins		
Cefazolin	15 mg/kg daily (for long dwell) ^{176,177} 20 mg/kg daily (for short dwell) ^{178,176}	LD 500 mg/L, MD 125 mg/L ^{d 168,179}
Cefepime	1000 mg daily	LD 500 mg/L, MD 125 mg/L
Cefoperazone	No data	LD 500 mg/L, MD 62.5–125 mg/L ¹⁸⁰
Cefotaxime	500–1000 mg daily ¹⁸¹	no data
Ceftazidime	1000–1500 mg daily (for long dwell) 20 mg/kg daily (for short dwell) ¹⁷⁸	LD 500 mg/L, MD 125 mg/L ^{d 168,182}
Ceftriaxone	1000 mg daily ¹⁸³	No data
Penicillins		
Penicillin G	No data	LD 50,000 unit/L, MD 25,000 unit/L ¹³
Amoxicillin	No data	MD 150 mg/L ¹⁸⁴
Ampicillin ^a	4 gm daily ¹⁸⁵	MD 125 mg/L ¹⁸⁶
Ampicillin/sulbactam		LD 1000 mg/500 mg, MD 133.3 mg/66.7 mg ^{187,188}
Piperacillin/tazobactam	No data	LD 4 gm/0.5 gm, MD 1 gm/0.125 gm ¹⁸⁹
Ticarcillin/clavulanic acid	No data	LD 3 gm/0.2 gm, MD 300 mg/20 mg/L ¹⁹⁰
Others		
Aztreonam	2 gm daily ¹⁹¹	LD 500 mg/L ¹⁹² , MD 250 mg/L ^{192,193}
Ciprofloxacin	No data	MD 50 mg/L ¹⁹⁴
Clindamycin	No data	MD 600 mg/bag ¹⁹⁵
Daptomycin	300 mg daily ¹⁹⁶	LD 100 mg/L ^{197,198,199} , MD 20 mg/L ^{197,200}
Fosfomycin	4 g daily ^{201,202}	No data
Imipenem/cilastatin	500 mg in alternate exchange ²⁰³	LD 250 mg/L, MD 50 mg/L ¹⁸²
Ofloxacin	No data	LD 200 mg, MD 25 mg/L ²⁰⁴
Polymyxin B	No data	MD 300,000 unit (30 mg)/bag ¹⁸⁸
Quinupristin/dalfopristin	25 mg/L in alternate exchanges ^{b205}	No data
Meropenem	500 mg daily (for long dwell in APD) ²⁰⁷ 1000 mg daily (for short dwell in CAPD) ^{208,209}	MD 125 mg/L ²⁰⁶
Teicoplanin	15 mg/kg every 5 days	LD 100 mg/bag, MD 20 mg/L
Vancomycin	15–30 mg/kg every 5–7 days ^{c141,212} for CAPD 15 mg/kg every 4 days ²¹³ for APD	LD 20–25 mg/kg, MD 25 mg/L ²¹⁴

Empiric Gram Negative Coverage

- Third generation Cephalosporin or Aminoglycoside
- Most popular choices Ceftazidime and Gentamicin
- ISPD Guidelines recommend intermittent dosing of gentamicin only

Table 5. IP antibiotic dosing recommendations for treatment of peritonitis.

Antibiotic	Intermittent (1 exchange daily for at least 6 h)	Continuous (all exchanges)
Aminoglycosides		
Amikacin	2 mg/kg daily	Not advised
Gentamicin	0.6 mg/kg daily ^{174,175}	Not advised
Netilmicin	0.6 mg/kg daily ¹⁶⁵	Not advised
Cephalosporins		
Cefazolin	15 mg/kg daily (for long dwell) ^{176,177} 20 mg/kg daily (for short dwell) ^{178,176}	LD 500 mg/L, MD 125 mg/L ^{d 168,179}
Cefepime	1000 mg daily	LD 500 mg/L, MD 125 mg/L ^{d 168}
Cefoperazone	No data	LD 500 mg/L, MD 62.5–125 mg/L ¹⁸⁰
Cefotaxime	500–1000 mg daily ¹⁶¹	no data
Ceftazidime	1000–1500 mg daily (for long dwell) 20 mg/kg daily (for short dwell) ¹⁷⁸	LD 500 mg/L, MD 125 mg/L ^{d 168,182}
Ceftazidime	1000 mg daily	No data
Penicillins		
Penicillin G	No data	LD 50,000 unit/L, MD 25,000 unit/L ¹³
Amoxicillin	No data	MD 150 mg/L ¹⁸⁴
Ampicillin ^a	4 gm daily ¹⁸⁵	MD 125 mg/L ¹⁸⁶
Ampicillin/sulbactam	No data	LD 1000 mg/500 mg, MD 133.3 mg/66.7 mg ^{187,188}
Piperacillin/tazobactam	No data	LD 4 gm/0.5 gm, MD 1 gm/0.125 gm ¹⁸⁹
Ticarcillin/clavulanic acid	No data	LD 3 gm/0.2 gm, MD 300 mg/20 mg/L ¹⁹⁰
Others		
Aztreonam	2 gm daily ¹⁹¹	LD 500 mg/L ¹⁹² , MD 250 mg/L ^{192,193}
Ciprofloxacin	No data	MD 50 mg/L ¹⁹⁴
Clindamycin	No data	MD 600 mg/bag ¹⁹⁵
Daptomycin	300 mg daily ¹⁹⁶	LD 100 mg/L ^{197,198,199} , MD 20 mg/L ^{197,200}
Fosfomycin	4 g daily ^{201,202}	No data
Imipenem/cilastatin	500 mg in alternate exchange ²⁰³	LD 250 mg/L, MD 50 mg/L ¹⁸²
Ofloxacin	No data	LD 200 mg, MD 25 mg/L ²⁰⁴
Polymyxin B	No data	MD 300,000 unit (30 mg)/bag ¹⁸⁸
Quinupristin/dalfopristin	25 mg/L in alternate exchanges ^{b205}	No data
Meropenem	500 mg daily (for long dwell in APD) ²⁰⁷ 1000 mg daily (for short dwell in CAPD) ^{208,209}	MD 125 mg/L ²⁰⁶
Teicoplanin	15 mg/kg every 5 days ²¹⁰	LD 400 mg/bag, MD 20 mg/L ^{211,140}
Vancomycin	15–30 mg/kg every 5–7 days ^{c141,212} for CAPD 15 mg/kg every 4 days ²¹³ for APD	LD 20–25 mg/kg, MD 25 mg/L ²¹⁴

Intermittent vs Continuous Dosing

- Intermittent Dosing
 - Antibiotics in 1 exchange each day
- Continuous Dosing
 - Antibiotics in all exchanges each day


ISPD guidelines allow the use of either dosing strategy

Therapeutic Principle


Ensure adequate local concentration of antibiotic in the peritoneal cavity to eliminate infection

- Intermittent Dosing
 - High concentration in 1 exchange each day
 - The body acts as a drug reservoir to deliver an adequate amount to the site of infection throughout the period between intermittent doses.
- Continuous Dosing
 - High concentration in all exchanges each day
 - Ensure that every PD bag is getting the correct amount of antibiotic


Pharmacology of Vancomycin in PD



Vancomycin must diffuse back into Peritoneal space during an exchange with no antibiotic



Modelled Drug Concentration in Intermittent vs Continuous Dosing



Case 1 Treatment

- Empiric treatment:
- Continuous dosing regimen
 - 1g Ceftazidime IP in first exchange 500mg in each exchange thereafter
 - 2g Vancomycin IP in first exchange 50mg in each exchange thereafter
 - Following levels of vancomycin to maintain a level > 15 mg/L
- Await culture/cell count data to determine final antibiotics choice and course duration

Case 2

- 38 year old man, 70kg
- ESRD secondary to GPA on PD for about 6 months.
- Avid soccer player, sweats all the time, doesn't clean the exit site well
- Presenting with cloudy fluid and abdominal pain
 - Current prescription CAPD is incremental
 - 2000cc Exchanges, 2-3x/day
 - Significant Residual Renal Function
 - Sleeps empty, or has other long periods of dry abdomen (playing soccer).
 - Even worse he does not dwell the full 2L volume each exchange

Case 2 Treatment

- Empiric treatment:
 - 1g Ceftazidime IP daily
 - 2g Vancomycin IP every other day to start
 - Following levels of vancomycin to maintain a level >15 mg/L
 - Day 3 culture Methicillin resistant Staph Epi (MRSE)
 - He needed 2g Vanco daily to maintain level >15 mg/L
 - Almost certainly was not dwelling 2L each exchange
 - Cleared after 2 weeks of treatment


Case 3

- 78 year old man, 70kg
- ESRD secondary to Diabetic Nephropathy on PD for about 1.5 years.
- Presenting with cloudy fluid and abdominal pain
 - Current prescription APD
 - 2000cc x4 cycles at night
 - 2000cc last fill
 - Some Residual Renal Function


Case 3 Treatment Considerations

- Empiric Gram Positive and Gram Negative Coverage
- Switch to CAPD?
 - Some patients would switch to CAPD and can use the previously mentioned empiric intermittent or continuous regimens
 - Generally, most patients will want to stay on APD

Modelled Drug Concentration in Intermittent vs Continuous Dosing



Pharmacologic Considerations in APD for Intermittent dosing of vancomycin



Vancomycin dosing in APD

- Not clear what serum vancomycin trough level is necessary for peritonitis resolution.
- Dialysate levels of vancomycin are lower than serum levels.

TABLE 2 Vancomycin				
Author/year	Type of study	Number of patients and peritonitis yes/no	Pharmacokinetic data	Outcomes
Manley 2001 (25)	Prospective observational Vancomycin 15 mg/kg given IV	10 APD no peritonitis	Yes	– Serum vancomycin and dialysate vancomycin levels above MIC only during 1st & 2nd dwell. – In APD vancomycin clearance is significant & daily IP dosing needed to provide adequate dialysate concentrations.
Fish 2012 (26)	Prospective observational Vancomycin 30 mg/kg IP Day 5 checked serum & dialysate vancomycin levels after a 4-h dwell	19 APD with peritonitis	Yes	– Serum vancomycin >12 mg/L 98% pts – Dialysate vancomycin <4 mg/L 23% pts – Conclude serum levels alone are not to be used to predict dialysate level due to low correlation coefficient – Suggest smaller more frequent dosing may be preferable
Mulhern 1995 (27)	Retrospective review Vancomycin 15 mg/kg IV Q week x 4	10 APD 21 CAPD All with peritonitis	Yes	– 9 episodes relapsed – Cumulative trough of <12 mg/L or initial day 7 trough <9 mg/L were predictive of relapse
Stevenson 2015 (28)	Retrospective cohort	3 APD 27 CAPD All with peritonitis	Yes	– Vancomycin levels were similar in patients achieving cure vs no cure – Conclude outcomes not associated with serum levels
Blunden 2010 (29)	Retrospective observational Vancomycin 25 mg/kg for anuric (increased by 25% for non-anuric)	120 APD 267 CAPD All with peritonitis	Yes	– Vancomycin level did not predict cure or relapse of gram-positive or culture-negative peritonitis
Schaefer 1999 (30)	Prospective observational Vancomycin 30 mg/L continuous dosing vs initial loading dose 15 mg/kg followed by 2nd dose of 30 mg/kg after 7 days	152 pediatric pts with 166 episodes of bacterial peritonitis Both APD and CAPD utilized (no breakdown given on number of APD vs CAPD)	No	– No breakdown between outcomes of CAPD and APD pts Overall: – No difference in relapse rate continuous vs intermittent vancomycin – Eradication of causative organism more frequent in continuous vs intermittent at both 60 hours ($p<0.001$) and 7 days ($p=0.004$)

APD = automated peritoneal dialysis; IV = intravenous; MIC = minimum inhibitory concentration; IP = intraperitoneal; pts = patients; CAPD = continuous ambulatory peritoneal dialysis; Q week = weekly.

Vancomycin dosing in APD

- Patients who relapsed had lower serum vancomycin levels (7.8 ± 0.6 mg/L during relapse vs 13.7 ± 0.9 mg/L during relapse-free episodes $p = 0.0004$)
- No episodes of relapsing peritonitis were found in patients with a mean serum vancomycin trough of > 16 mg/L. This is higher than the 15 mg/L recommended by ISPD.

Author/year	Type of study	Number of patients and peritonitis yes/no	Pharmacokinetic data	Outcomes
Manley 2001 (25)	Prospective observational Vancomycin 15 mg/kg given IV	10 APD no peritonitis	Yes	<ul style="list-style-type: none"> – Serum vancomycin and dialysate vancomycin levels above MIC only during 1st & 2nd dwell. – In APD vancomycin clearance is significant & daily IP dosing needed to provide adequate dialysate concentrations.
Fish 2012 (26)	Prospective observational Vancomycin 30 mg/kg IP Day 5 checked serum & dialysate vancomycin levels after a 4-h dwell	19 APD with peritonitis	Yes	<ul style="list-style-type: none"> – Serum vancomycin >12 mg/L 98% pts – Dialysate vancomycin <4 mg/L 23% pts – Conclude serum levels alone are not to be used to predict dialysate level due to low correlation coefficient – Suggest smaller more frequent dosing may be preferable
Mulhern 1995 (27)	Retrospective review Vancomycin 15 mg/kg IV Q week $\times 4$	10 APD 21 CAPD All with peritonitis	Yes	<ul style="list-style-type: none"> – 9 episodes relapsed – Cumulative trough of <12 mg/L or initial day 7 trough <9 mg/L were predictive of relapse
Stevenson 2015 (28)	Retrospective cohort	3 APD 27 CAPD All with peritonitis	Yes	<ul style="list-style-type: none"> – Vancomycin levels were similar in patients achieving cure vs no cure – Conclude outcomes not associated with serum levels
Blunden 2010 (29)	Retrospective observational Vancomycin 25 mg/kg for anuric (increased by 25% for non-anuric)	120 APD 267 CAPD All with peritonitis	Yes	<ul style="list-style-type: none"> – Vancomycin level did not predict cure or relapse of gram-positive or culture-negative peritonitis
Schaefer 1999 (30)	Prospective observational Vancomycin 30 mg/L continuous dosing vs initial loading dose 15 mg/kg followed by 2nd dose of 30 mg/kg after 7 days	152 pediatric pts with 166 episodes of bacterial peritonitis Both APD and CAPD utilized (no breakdown given on number of APD vs CAPD)	No	<ul style="list-style-type: none"> – No breakdown between outcomes of CAPD and APD pts Overall: <ul style="list-style-type: none"> – No difference in relapse rate continuous vs intermittent vancomycin – Eradication of causative organism more frequent in continuous vs intermittent at both 60 hours ($p<0.001$) and 7 days ($p=0.004$)

APD = automated peritoneal dialysis; IV = intravenous; MIC = minimum inhibitory concentration; IP = intraperitoneal; pts = patients; CAPD = continuous ambulatory peritoneal dialysis; Q week = weekly.

Ceftazidime in APD


- ISPD guidelines recommend an intermittent once-daily dose
- Studied in CAPD but is widely extrapolated to APD.

Case 3 Treatment

- Empiric Regimen:
 - 1g Ceftazidime daily in the long day dwell
 - 2g vancomycin every 3 days in the long day dwell
 - Following levels of vancomycin to maintain a level >15 mg/L

Considerations for the patient

- Ceftazidime/Cefazolin ISPD recommended continuous dosing
 - LD 500 mg/L, MD 125 mg/L



Conclusions

- Empiric antibiotics for PD peritonitis should focus on ensuring adequate coverage, dosing, delivery, and duration of medication
- CAPD patients are the reference case, intermittent vs continuous dosing can be used and advantages and disadvantages understood.
- Increased clearance with APD patients must be accounted for in terms of antibiotic dosing.

Questions?

- Questions?